NZ777273A - Factor xi antibodies and methods of use - Google Patents

Factor xi antibodies and methods of use

Info

Publication number
NZ777273A
NZ777273A NZ777273A NZ77727316A NZ777273A NZ 777273 A NZ777273 A NZ 777273A NZ 777273 A NZ777273 A NZ 777273A NZ 77727316 A NZ77727316 A NZ 77727316A NZ 777273 A NZ777273 A NZ 777273A
Authority
NZ
New Zealand
Prior art keywords
seq
variable region
chain variable
subject
heavy chain
Prior art date
Application number
NZ777273A
Other versions
NZ777273B2 (en
Inventor
Jorg Eder
Stefan Ewert
Ulrich Hassiepen
Yasser Khder
Lorenz M Mayr
Samu Melkko
Nikolaus Schiering
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from NZ738480A external-priority patent/NZ738480B2/en
Publication of NZ777273A publication Critical patent/NZ777273A/en
Publication of NZ777273B2 publication Critical patent/NZ777273B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (”Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Claims (25)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. Use of an antibody or antigen-binding fragment thereof in the manufacture of a medicament for the treatment of a thromboembolic disorder in a subject afflicted with or at risk of developing a thromboembolic disorder, n the antibody or antigen-binding fragment thereof is to be administered to the subject at a dose of at least 90 mg, and wherein the antibody or antigen-binding fragment thereof comprises: i. a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain le region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain variable region CDR3 of SEQ ID NO: 35; ii. a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain le region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38; iii. a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or iv. a heavy chain le region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain le region CDR3 of SEQ ID NO: 5; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.
2. The use of claim 1, wherein: (i) the antibody or antigen-binding fragment thereof comprises a variable region heavy chain of SEQ ID NO: 9 and a variable region light chain sequence of SEQ ID NO: (ii) the antibody or antigen-binding fragment thereof comprises a le region heavy chain of SEQ ID NO: 29 and a variable region light chain sequence of SEQ ID NO: (iii) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid ce of SEQ ID NO: 41; (iv) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and a light chain comprising the amino acid sequence of SEQ ID NO: 21.
3. The use of claim 2, wherein the antibody comprises D265A and P329A substitutions in the Fc .
4. The use of any one of claims 1-3, wherein the subject is afflicted with or at risk of developing a thromboembolic disorder ed from the group consisting of: venous thromboembolism, smal atrial fibrillation or atrial flutter, stroke associated with atrial fibrillation or atrial flutter, deep vein thrombosis (DVT), cancer, transient ischemic attack, severe protein S deficiency, thromboembolic stroke, ischemic stroke, ic embolism, and dial infarction.
5. The use of any one of claims 1-4, wherein the subject is afflicted with one or more of stroke associated with atrial fibrillation and deep vein thrombosis.
6. The use of any one of claims 1-5, n the subject is ted with stroke associated with atrial fibrillation or atrial flutter.
7. The use of claim 6, wherein the atrial fibrillation or atrial flutter is paroxysmal atrial fibrillation (PAF).
8. The use of any one of claims 1-4, wherein the subject is afflicted with or at risk of developing venous thromboembolism.
9. The use of any one of claims 1-5, wherein the subject is afflicted with or at risk of developing deep vein thrombosis (DVT).
10. The use of claim 8 or 9, the treatment further comprising measuring efficacy by incidence of DVT occurrence.
11. The use of any one of claims 1-10, wherein the subject is at high risk for
12. The use of any one of claims 1-4 or 8-11, n the subject has undergone a medical procedure selected from the group consisting of knee replacement surgery, hip replacement surgery, orthopedic surgery, pacemaker installation, catheter installation, thoracic surgery, and abdominal surgery.
13. The use of claim 12, wherein the l procedure is knee replacement surgery.
14. The use of any one of claims 1-7, wherein the subject at risk is afflicted with one or more of hypertension, congestive heart failure, left ventricular hypertrophy, and diabetes mellitus.
15. The use of any one of claims 1-14, the treatment further comprising evaluating efficacy of the antibody or antigen-binding fragment thereof by one or more biomarkers selected from the group ting of free Factor XI, total Factor XI, Factor XI coagulation activity, activated partial thromboplastin time, and D-dimer.
16. The use of any one of claims 1-15, the treatment further comprising ting adverse events to the antibody or antigen-binding fragment thereof by measuring bleeding events and/or the presence of anti-drug antibodies.
17. The use of claim 16, the ent further comprising applying one or more of the following to the patient experiencing an adverse event, wherein the adverse event is a bleeding event: (i) fluid replacement using colloids, crystalloids, human plasma, or plasma proteins, such as albumin; (ii) transfusion with packed red blood or whole blood; or (iii) administration of fresh frozen plasma (FFP), prothrombin complex concentrates (PCC), or activated PCC (APCC), such as factor VIII inhibitor and/or recombinant ted factor VII.
18. The use of any one of claims 1-17, the treatment further comprising stration to the subject afflicted with or at risk of developing a thromboembolic disorder an effective amount of a statin therapy.
19. The use of any one of claims 1-18, wherein a dose of about 150 mg of the antibody or antigen-binding fragment thereof is to be stered to the subject.
20. The use of any one of claims 1-19, wherein the antibody or n-binding fragment thereof is to be stered to the subject subcutaneously or intravenously.
21. The use of any one of claims 1-20, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject once a month.
22. The use of any one of claims 1-21, wherein the antibody or antigen-binding nt thereof is to be administered to the subject in a pharmaceutical composition further sing sucrose, a polysorbate, idine, and histidine HCl monohydrate.
23. The use of claim 22, wherein the pharmaceutical composition is at a pH of about 5.5.
24. The use of any one of claims 1-23, wherein the dy or antigen-binding fragment thereof is an anti-Factor XI (FXI) and/or anti-activated Factor XI (FXIa) antibody or antigen-binding fragment thereof.
25. The use of claim 1, substantially as herein described with reference to any one of the examples and/or
NZ777273A 2016-06-24 Factor XI antibodies and methods of use NZ777273B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184955P 2015-06-26 2015-06-26
US201662341568P 2016-05-25 2016-05-25
NZ738480A NZ738480B2 (en) 2016-06-24 Factor xi antibodies and methods of use

Publications (2)

Publication Number Publication Date
NZ777273A true NZ777273A (en) 2025-05-30
NZ777273B2 NZ777273B2 (en) 2025-09-02

Family

ID=

Also Published As

Publication number Publication date
TW202222839A (en) 2022-06-16
ZA201708589B (en) 2018-11-28
AU2019264514A1 (en) 2019-12-05
CN114380914A (en) 2022-04-22
US20180355056A1 (en) 2018-12-13
DK3313891T3 (en) 2026-06-15
JP2018526976A (en) 2018-09-20
NZ738480A (en) 2025-03-28
PH12021551700A1 (en) 2022-11-07
LT3313891T (en) 2026-06-25
CL2017003261A1 (en) 2018-04-20
RU2020142517A (en) 2021-01-27
RU2018102798A3 (en) 2020-05-22
IL295859B1 (en) 2025-03-01
JP6698711B2 (en) 2020-05-27
MY185813A (en) 2021-06-10
SG10201913262RA (en) 2020-03-30
MA42243A (en) 2018-05-02
AU2019264514B2 (en) 2021-12-09
WO2016207858A1 (en) 2016-12-29
RU2018102798A (en) 2019-07-29
JP2022116069A (en) 2022-08-09
SI3313891T1 (en) 2026-07-31
RU2739946C2 (en) 2020-12-30
RS68174B1 (en) 2026-06-30
MX2017017144A (en) 2018-05-28
IL256376B (en) 2022-09-01
EP3313891B1 (en) 2026-04-01
AU2025201731A1 (en) 2025-04-03
HK1250990A1 (en) 2019-01-18
EA036395B1 (en) 2020-11-05
CO2017013356A2 (en) 2018-03-20
JOP20160131B1 (en) 2022-03-14
CA2990764A1 (en) 2016-12-29
MX391310B (en) 2025-03-21
JP7587550B2 (en) 2024-11-20
EP3313891A1 (en) 2018-05-02
KR20190142448A (en) 2019-12-26
KR20180019733A (en) 2018-02-26
JP2024026169A (en) 2024-02-28
TWI743039B (en) 2021-10-21
TWI820482B (en) 2023-11-01
IL295859B2 (en) 2025-07-01
AU2021273615A1 (en) 2021-12-16
BR112017027778A2 (en) 2018-10-09
IL295859A (en) 2022-10-01
AU2016281957A1 (en) 2018-01-18
UY36751A (en) 2017-01-31
CU24498B1 (en) 2021-01-12
JP7823009B2 (en) 2026-03-03
JOP20200312A1 (en) 2020-12-03
PH12017502358A1 (en) 2018-06-25
CR20170600A (en) 2018-02-28
AU2021273615B2 (en) 2024-12-12
MY194928A (en) 2022-12-23
US10465011B2 (en) 2019-11-05
HRP20260688T1 (en) 2026-07-17
US20240067750A1 (en) 2024-02-29
AU2016281957B2 (en) 2019-08-15
MA42243B1 (en) 2026-05-26
CN107922505B (en) 2022-05-06
IL318883A (en) 2025-04-01
TW201722993A (en) 2017-07-01
US20170022292A1 (en) 2017-01-26
KR102059059B1 (en) 2020-02-12
PT3313891T (en) 2026-06-17
US20200115468A1 (en) 2020-04-16
TN2017000536A1 (en) 2019-04-12
ECSP18005520A (en) 2018-04-30
PL3313891T3 (en) 2026-07-27
EA201890145A1 (en) 2018-07-31
JP2026076151A (en) 2026-05-11
IL256376A (en) 2018-02-28
MX2022004072A (en) 2022-05-03
CN114773479A (en) 2022-07-22
CU20170169A7 (en) 2018-07-05
EP4763864A2 (en) 2026-06-24
CN107922505A (en) 2018-04-17
PE20180480A1 (en) 2018-03-07
FI3313891T3 (en) 2026-05-26
JP2020114216A (en) 2020-07-30
ES3073133T3 (en) 2026-07-08

Similar Documents

Publication Publication Date Title
JP2022536511A (en) Use of activatable anti-PDL1 and anti-CTLA-4 antibodies in combination therapy for the treatment of cancer
JP6193871B2 (en) Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for preventing or reducing organ dysfunction or organ failure in patients suffering from chronic or acute diseases or conditions
EA201992590A1 (en) STABLE COMPOSITIONS OF ANTIBODIES TO THE RECIPE OF PROGRAMMABLE DAMAGE 1 (PD-1) AND WAYS OF THEIR APPLICATION
CN111971062A (en) Monoclonal antibody preparation for resisting human PD-1, combined medicament and application thereof
US20120244161A1 (en) DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY
US9932397B2 (en) VEGFA/Ang2 Compounds
KR102296017B1 (en) Treating vascular disease and complications thereof
BR112020000162A2 (en) bispecific antibodies checkpoint inhibitors
RU2017127772A (en) HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS
WO2020259605A1 (en) Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof
CN102027015A (en) Anti-CXCR4 antibodies
JP2014533671A (en) Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy
JP7114491B2 (en) Anti-Mac-1 antibody
JP2015502349A (en) Anti-adrenomedullin (ADM) antibody, anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in the treatment of acute disease or condition in a patient to stabilize blood circulation
RU2014145841A (en) Therapeutic biological product for the treatment of hepatocellular carcinoma
JP2023507795A5 (en)
FI3463436T3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
JP2015096065A5 (en)
Metzger Filho et al. Prevention and management of major side effects of targeted agents in breast cancer
EA039433B1 (en) COMBINED TREATMENT WITH DRUGS INTERFERING WITH NETRIN-1 AND DRUGS INHIBITORS OF IMMUNE RESPONSE CHECKPOINTS
CN109793892B (en) Application of anti-PD-1 antibody in preparation of medicine for treating esophageal cancer
KR20240038008A (en) Cancer treatment methods and compositions
JP2024519450A (en) Anti-galectin-9 antibodies and therapeutic uses thereof
WO2017064034A1 (en) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
NZ777273B2 (en) Factor XI antibodies and methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed